Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Acelyrin, Inc. (SLRN) Insider Trading Activity
Healthcare • Biotechnology • 93 employees
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Total Value
$20,000.00
Total Shares
825,000
Average Trade Value
$6,666.67
Most Active Insider
Murugan Amar
Total Activity: $10,000
Largest Single Transaction
$10,000
by Murugan Amar on Jan 23, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Legal Officer
Officer
|
Jan 23, 2025 | 125,000 | $10,000 | 125,500 (+99.6%) | Grant | |
|
Chief Executive Officer
Director, Officer
|
Jan 23, 2025 | 575,000 | $0 | 689,739 (+83.4%) | Grant | |
|
Chief Medical Officer
Officer
|
Jan 23, 2025 | 125,000 | $10,000 | 125,000 (+100.0%) | Grant |